DE3739690A1
(de)
*
|
1987-11-24 |
1989-06-08 |
Hoechst Ag |
Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
|
IL88502A
(en)
*
|
1987-12-14 |
1993-04-04 |
Squibb & Sons Inc |
Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US6300362B1
(en)
|
1990-07-25 |
2001-10-09 |
Novartis Ag (Formerly Sandoz Ltd.) |
Stabilized pharmaceutical compositions comprising acid donors
|
HU222489B1
(hu)
*
|
1990-07-25 |
2003-07-28 |
Novartis Ag. |
Stabilizált gyógyszerkészítmények és eljárás az előállításukra
|
US5292520A
(en)
*
|
1990-09-13 |
1994-03-08 |
Akzo N.V. |
Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
|
DK0475482T3
(da)
|
1990-09-13 |
1995-04-03 |
Akzo Nobel Nv |
Stabiliserede faste kemiske midler
|
US5124337A
(en)
*
|
1991-05-20 |
1992-06-23 |
Schering Corporation |
N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
|
US5238935A
(en)
*
|
1991-05-20 |
1993-08-24 |
Schering Corporation |
N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
|
FR2665834B1
(fr)
*
|
1991-07-24 |
2001-02-23 |
Sandoz Sa |
Composition pharmaceutique stabilisee par un donneur d'acide chlorhydrique, et sa preparation.
|
TW284688B
(da)
*
|
1991-11-20 |
1996-09-01 |
Takeda Pharm Industry Co Ltd |
|
YU48602B
(sh)
*
|
1991-11-25 |
1998-12-23 |
Krka Tovarna Zdravil P.O. |
Postupak za dobijanje stabilne formulacije soli enalaprila
|
TW483763B
(en)
*
|
1994-09-02 |
2002-04-21 |
Astra Ab |
Pharmaceutical composition comprising of ramipril and dihydropyridine compound
|
US5573780A
(en)
*
|
1995-08-04 |
1996-11-12 |
Apotex Usa Inc. |
Stable solid formulation of enalapril salt and process for preparation thereof
|
US6296871B1
(en)
|
1998-04-12 |
2001-10-02 |
Ranbaxy Laboratories Limited |
Stable solid pharmaceutical compositions containing enalapril maleate
|
NZ508544A
(en)
*
|
1998-06-05 |
2002-10-25 |
Warner Lambert Co |
Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
NZ333206A
(en)
*
|
1998-12-08 |
2000-07-28 |
Bernard Charles Sherman |
Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
|
US20030027837A1
(en)
*
|
1998-12-08 |
2003-02-06 |
Sherman Bernard Charles |
Pharmaceutical compositions comprising quinapril magnesium
|
US6637359B1
(en)
*
|
1998-12-15 |
2003-10-28 |
Maritrans Inc. |
System and method for internally fitting a new inner hull to an existing outer hull to form a rebuilt double hull vessel
|
US6060461A
(en)
*
|
1999-02-08 |
2000-05-09 |
Drake; James Franklin |
Topically applied clotting material
|
MY121470A
(en)
*
|
1999-05-03 |
2006-01-28 |
Ranbaxy Lab Ltd |
Stable solid pharmaceutical compositions containing enalapril maleate
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
RU2276997C2
(ru)
*
|
1999-08-30 |
2006-05-27 |
Санофи-Авентис Дойчланд Гмбх |
Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
|
US6764694B1
(en)
*
|
1999-08-31 |
2004-07-20 |
Mutual Pharmaceutical Co., Inc. |
Stable formulations of ACE inhibitors, and methods for preparation thereof
|
US6555551B1
(en)
|
1999-08-31 |
2003-04-29 |
Mutual Pharmaceutical Co., Inc. |
Stable formulations of ACE inhibitors, and methods for preparation thereof
|
US20030225124A1
(en)
*
|
1999-08-31 |
2003-12-04 |
Spiridon Spireas |
Stable formulations of ACE inhibitors, and methods for preparation thereof
|
US20040157911A1
(en)
*
|
1999-08-31 |
2004-08-12 |
Spiridon Spireas |
Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
|
GB0001621D0
(en)
|
2000-01-26 |
2000-03-15 |
Astrazeneca Ab |
Pharmaceutical compositions
|
CA2303481A1
(en)
*
|
2000-04-05 |
2001-10-05 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising moexipril magnesium
|
US6333332B1
(en)
*
|
2000-08-25 |
2001-12-25 |
Impax Laboratories, Inc. |
Stabilized pharmaceutical compositions containing bupropion hydrochloride
|
TWI232102B
(en)
*
|
2001-07-17 |
2005-05-11 |
Shionogi & Co |
A pharmaceutical formulation for injection
|
US20040170689A1
(en)
*
|
2001-11-09 |
2004-09-02 |
Odink Debra Alida |
Stabilized formulations comprising hydrolytically unstable compositions
|
AU2003201071A1
(en)
*
|
2002-01-15 |
2003-07-30 |
Ranbaxy Laboratories Limited |
Stable pharmaceutical compositions comprising ace inhibitor(s)
|
WO2003059388A1
(en)
*
|
2002-01-15 |
2003-07-24 |
Delta Hf. |
Formulations of quinapril and related ace inhibitors
|
US20030157165A1
(en)
*
|
2002-02-01 |
2003-08-21 |
Sherman Bernard Charles |
Stable saccharide-free tablets comprising a salt of quinapril or moexipril
|
US20030215526A1
(en)
*
|
2002-03-08 |
2003-11-20 |
Scott Stofik |
Stable formulations of angiotensin converting enzyme (ACE) inhibitors
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
PL1635792T3
(pl)
*
|
2003-06-26 |
2009-08-31 |
Teva Pharmaceutical Industries Ltd |
Stabilne kompozycje farmaceutyczne pochodnych kwasu 2-aza-bicyklo[3.3.0]-oktano-3-karboksylowego
|
US6869963B2
(en)
*
|
2003-07-11 |
2005-03-22 |
Sandoz Ag |
Stable pharmaceutical compositions containing an ACE inhibitor
|
AU2003270245A1
(en)
*
|
2003-09-23 |
2005-04-11 |
Texcontor Etablissement |
Stable quinapril compositions
|
US20050181055A1
(en)
*
|
2003-10-08 |
2005-08-18 |
Mathur Rajeev S. |
Pharmaceutical compositions of quinapril
|
EP1694308A1
(en)
*
|
2003-10-30 |
2006-08-30 |
Lupin Ltd. |
Stable formulations of ace inhibitors and methods for preparation thereof
|
GB2411355B
(en)
|
2004-02-27 |
2006-02-22 |
Niche Generics Ltd |
Pharmaceutical composition
|
EP1734931A2
(en)
*
|
2004-03-24 |
2006-12-27 |
Actavis Group |
Formulations of ramipril
|
EA011712B1
(ru)
*
|
2004-03-29 |
2009-04-28 |
Ле Лаборатуар Сервье |
Способ производства твёрдой фармацевтической композиции
|
SI21800A
(sl)
|
2004-05-14 |
2005-12-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Nov postopek sinteze perindoprila
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
JP2008024592A
(ja)
*
|
2005-01-28 |
2008-02-07 |
Taisho Pharmaceut Co Ltd |
シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
|
GR1006875B
(el)
*
|
2005-06-30 |
2010-07-12 |
"Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., |
Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
|
GB0518129D0
(en)
*
|
2005-09-06 |
2005-10-12 |
Arrow Int Ltd |
Ramipril formulation
|
US20070098782A1
(en)
*
|
2005-10-28 |
2007-05-03 |
Selamine Limited |
Ramipril Formulation
|
GB2431579A
(en)
*
|
2005-10-28 |
2007-05-02 |
Arrow Int Ltd |
Ramipril formulations
|
PL1948224T3
(pl)
|
2005-11-17 |
2014-10-31 |
Silverstone Pharma Est |
Trwały preparat amorficznych soli peryndoprylu, sposób ich wytwarzania, zwłaszcza wytwarzania w skali przemysłowej oraz ich zastosowanie w terapii nadciśnienia
|
EP1815857A1
(en)
|
2006-02-02 |
2007-08-08 |
LEK Pharmaceuticals D.D. |
A pharmaceutical composition comprising perindopril
|
US20070232680A1
(en)
*
|
2006-04-04 |
2007-10-04 |
Vijayabhaskar Bolugoddu |
Preparation of ramipril and stable pharmaceutical compositions
|
US7943655B2
(en)
*
|
2006-04-05 |
2011-05-17 |
Universitat Zurich |
Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CA2810839A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
|
US20100035955A1
(en)
*
|
2006-06-30 |
2010-02-11 |
Panagiotis Keramidas |
Stabilised Composition Comprising ACE Inhibitors
|
GB0624087D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril combination salt
|
GB0624084D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril amino acid salts
|
GB0624090D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril amine salts
|
CN101784278A
(zh)
*
|
2007-08-17 |
2010-07-21 |
贝林格尔.英格海姆国际有限公司 |
用于治疗fab-相关的疾病的嘌呤衍生物
|
JP2009084242A
(ja)
*
|
2007-10-02 |
2009-04-23 |
Nichi-Iko Pharmaceutical Co Ltd |
安定性に優れた塩酸テモカプリル錠剤
|
JP5113476B2
(ja)
*
|
2007-10-09 |
2013-01-09 |
沢井製薬株式会社 |
保存安定性に優れた塩酸テモカプリルの錠剤
|
EP2211906A2
(en)
*
|
2007-11-07 |
2010-08-04 |
Janssen Pharmaceutica, N.V. |
Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
|
WO2009113081A1
(en)
*
|
2008-03-10 |
2009-09-17 |
Lupin Limited |
Tris (hydroxymethyl ) amino methane salt of quinapril and ramipril
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
MX370599B
(es)
*
|
2008-08-15 |
2019-12-18 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
TR200906322A2
(tr)
|
2009-08-17 |
2011-07-21 |
Bi̇lgi̇ç Mahmut |
Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
|
ES2364011B1
(es)
|
2009-11-20 |
2013-01-24 |
Gp Pharm, S.A. |
Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
SI2585051T2
(sl)
|
2010-06-23 |
2020-07-31 |
Krka, D.D., Novo Mesto |
Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
WO2012085249A2
(en)
|
2010-12-24 |
2012-06-28 |
Krka, D.D., Novo Mesto |
Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
DK2731947T3
(da)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
Substitueret dimerisk quinazolin-derivat, fremstilling og andvendelse deraf i farmaceutiske sammensætninger til behandling af type i- og type ii-diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US8568747B1
(en)
|
2012-10-05 |
2013-10-29 |
Silvergate Pharmaceuticals, Inc. |
Enalapril compositions
|
PL227900B1
(pl)
|
2012-11-15 |
2018-01-31 |
Adamed Spolka Z Ograniczona Odpowiedzialnoscia |
Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
|
US9937153B2
(en)
|
2013-08-30 |
2018-04-10 |
Merck Sharp & Dohme Ltd. |
Oral pharmaceutical formulation of omarigliptin
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
SI3193826T1
(sl)
|
2014-07-31 |
2019-02-28 |
Pharmathen S.A. |
Orodisperzibilen filmski sestavek, ki obsega enalapril, za zdravljenje hipertenzije pri pediatrični populaciji
|
BR112017002827B1
(pt)
|
2014-08-28 |
2023-04-18 |
Eisai R&D Management Co., Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
MX2017010474A
(es)
|
2015-02-25 |
2017-11-28 |
Eisai R&D Man Co Ltd |
Metodo para suprimir el amargor de un derivado de quinoleina.
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
SG11201710198YA
(en)
|
2015-06-16 |
2018-01-30 |
Eisai R&D Man Co Ltd |
Anticancer agent
|
US9463183B1
(en)
|
2015-10-30 |
2016-10-11 |
Silvergate Pharmaceuticals, Inc. |
Lisinopril formulations
|
WO2017077425A1
(en)
|
2015-11-07 |
2017-05-11 |
Ftf Pharma Private Limited |
Oral solution of ace inhibitors
|
US9669008B1
(en)
|
2016-03-18 |
2017-06-06 |
Silvergate Pharmaceuticals, Inc. |
Enalapril formulations
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|